A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
This study is ongoing, but not recruiting participants.
First Posted: November 11, 2010
Last Update Posted: December 6, 2016
Quebec Clinical Research Organization in Cancer
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||December 2016|
|Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodoulopoulos R, Rousseau C, Johnson N, Crump M, Morin RD, Mann KK. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016 Jul 14;128(2):185-94. doi: 10.1182/blood-2016-02-699520. Epub 2016 May 10.